Effects of mindfulness-based cognitive therapy on breast cancer survivors with insomnia: A randomised controlled trial.
Study Goal
The researchers aimed to determine whether mindfulness-based cognitive therapy for insomnia (MBCT-I) could improve sleep quality and mindfulness in breast cancer survivors.
Results Summary
MBCT-I significantly reduced insomnia severity and improved sleep measures (e.g., decreased sleep onset latency, increased total sleep time) compared to the control group. Mindfulness levels also increased significantly in the MBCT-I group at all follow-up points.
Population
Breast cancer survivors with insomnia.
Effective Dosage
Not specified
Duration
Intervention duration not explicitly stated, but follow-ups occurred at post-intervention, 3 months, and 6 months.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
mindfulness-based cognitive therapy on insomnia (MBCT-I) | decrease | Insomnia severity | breast cancer survivors | - | decreased significantly | #1 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | decrease | insomnia status | breast cancer survivors with moderate and severe insomnia | 59.6% | improved | #2 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | decrease | sleep onset latency | breast cancer survivors | - | decreased | #3 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | decrease | waking after sleep onset | breast cancer survivors | - | decreased | #4 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | increase | total sleep time | breast cancer survivors | - | increased | #5 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | increase | sleep efficiency | breast cancer survivors | - | increased | #6 |
mindfulness-based cognitive therapy on insomnia (MBCT-I) | increase | Mindfulness | breast cancer survivors | - | increased more | #7 |
OBJECTIVE: We investigated the effects of mindfulness-based cognitive therapy on insomnia (MBCT-I) in breast cancer survivors. METHODS: In total, 136 participants were allocated randomly to a MBCT-I group or a waitlist control (WLC) group. Indicators of insomnia and mindfulness were evaluated using the Insomnia Severity Index, actigraphy and the Five Facet Mindfulness Questionnaire. Data were collected at baseline (T1), post-intervention (T2), 3-month follow-up (T3) and 6-month follow-up (T4) time points. RESULTS: Insomnia severity decreased significantly in the MBCT-I group, compared with the WLC group, at T2, T3 and T4 (all p < .001). We found that 59.6% of the MBCT-I group with moderate and severe insomnia improved to no insomnia and subclinical insomnia at T4 relative to T1, accounting for 7.9% and 55.3%, respectively. Compared with the WLC group, the MBCT-I group improved on actigraphy measures of sleep; they exhibited a pattern of decreased sleep onset latency and waking after sleep onset, as well as increased total sleep time and sleep efficiency. Mindfulness also increased more in the MBCT-I group than in the WLC group at T2, T3 and T4 (all p < .001). CONCLUSIONS: MBCT-I may be an efficacious non-pharmacologic intervention to improve sleep quality in breast cancer survivors.